CS MEDICA A/S signs partnership with Ampilio in preparation of Amazon expansion
CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the Company has signed a partnership with Ampilio AB (“Ampilio”), a subsidiary of SpectrumOne. Ampilio will assist CS MEDICA as a business strategist, growth specialist as CS MEDICA prepares to execute global expansion on Amazon. The agreement comprises that Ampilio will run sales activities and develop a digital strategy and assist CS MEDICA in the global launch on Amazon. The partnership is a running agreement with a fixed annual fee of 270 000 SEK.
CS MEDICA is currently working on expanding the Company’s marketing activities and global presence. One of the future operational objectives of the Company is to launch Amazon sales channel in Sweden, Germany and France during the second half of the financial year 2021/2022. To reach the growth aspirations and maximize the competitive advantage on the new platform, strategic alliances will help the execution of the overall business strategy.
CS MEDICA announces today that the Company has signed a partnership with Ampilio, a subsidiary of SpectrumOne. Ampilio has developed a service to handle customers’ sales activities on Amazon’s platform. Mainly, Ampilio will assist CS MEDICA as a strategic partner and growth agency. As a business strategist and growth specialist, Ampilio aims to assist CS MEDICA to prepare the Amazon expansion by running all sales activities and develop a digital strategy.
“The strategy to build strong customer relationships drive sales, sustainability, and growth, this is something we see that the SpectrumOne group has delivered for their clients’ time and time again so our choice to work with them couldn’t have been easier, we have one of the best revolutionary CBD medical products on the market and with Ampilios help they will deliver this message to the world market and create lifelong relationships with our customers,” comments Gitte Henriksen, CFO, CS MEDICA.
Hosni Teque-Omeirat, CEO, SpectrumOne, comments:
“Us attracting, and given the opportunity to work with, agile and dedicated companies with strong and result-oriented managements seeing the importance of a partner that is data-driven and leaning on digital and automation rather than man-hours, is truly fulfilling and a great part of our job. Having read through CS MEDICAL’S financial goals I am intensely aware of the vigorous year that is awaiting them regarding sales and activities and getting the opportunity to support and being part of that journey is strongly encouraging.”
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.
Tags: